Hemophilia A (HA) is a rare bleeding disorder caused by reduced or absent clotting factor VIII (FVIII) activity due to mutation in its coding gene (F8). [1] FVIII replacement is required lifelong to treat bleeding, especially in severe cases (FVIII activity below 0.01 international units [IU]/mL). [1] Besides that, up to 44% of people with HA (PwHA) may develop neutralizing antibodies against exogenous FVIII (inhibitors). [2] The presence of inhibitors predispose PwHA to severe bleeding, [3] and increased morbidity and mortality. [4,5] The treatment of choice for persistent, high-responding inhibitors is immune tolerance induction (ITI), which consists of frequent and long-term infusions of FVIII. [1] Success rates among different ITI regimens range from 60%-90%. [6]